| Date Filed | Type | Description |
| 06/02/2023 |
4
| Bazemore Todd (SEE REMARKS) has filed a Form 4 on Kala Pharmaceuticals, Inc.|
Txns:
| Granted 21,158 shares
@ $0
Disposed/sold 3,439 options to buy
@ $0
Disposed/sold 499 options to buy
@ $0
Disposed/sold 3,499 options to buy
@ $0
Disposed/sold 2,400 options to buy
@ $0
Disposed/sold 2,199 options to buy
@ $0
Disposed/sold 4,759 options to buy
@ $0
Disposed/sold 864 options to buy
@ $0 |
|
| 03/15/2023 |
4
| Bazemore Todd (SEE REMARKS) has filed a Form 4 on Kala Pharmaceuticals, Inc.|
Txns:
| Granted 576 options to buy
@ $68.5, valued at
$39.5k
|
|
| 01/30/2023 |
4
| Bazemore Todd (Director) has filed a Form 4 on Pulmatrix, Inc.|
Txns:
| Granted 1,700 options to buy
@ $3.99, valued at
$6.8k
|
|
| 01/06/2023 |
4
| Bazemore Todd (SEE REMARKS) has filed a Form 4 on Kala Pharmaceuticals, Inc.|
Txns:
| Granted 12,800 shares
@ $0
Sold 62 shares
@ $28.54, valued at
$1.8k
|
|
| 10/28/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/29/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/28/2022 |
4
| Bazemore Todd (Director) has filed a Form 4 on Pulmatrix, Inc.|
Txns:
| Granted 22,100 options to buy
@ $0.3701, valued at
$8.2k
|
|
| 01/05/2022 |
4
| Bazemore Todd (SEE REMARKS) has filed a Form 4 on Kala Pharmaceuticals, Inc.|
Txns:
| Sold 3,454 shares
@ $1.3, valued at
$4.5k
Granted 238,000 options to buy
@ $1.37, valued at
$326.1k
|
|
| 10/28/2021 |
4
| Bazemore Todd (COO) has filed a Form 4 on Kala Pharmaceuticals, Inc.|
Txns:
| Sold 12,544 shares
@ $1.8, valued at
$22.6k
|
|
| 06/29/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/01/2021 |
4
| Bazemore Todd (Director) has filed a Form 4 on Pulmatrix, Inc.|
Txns:
| Granted 15,000 options to buy
@ $1.47, valued at
$22.1k
|
|
| 01/05/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/28/2020 |
4
| Bazemore Todd (COO) has filed a Form 4 on Kala Pharmaceuticals, Inc.|
Txns:
| Granted 81,000 shares
@ $0
Bought 2 shares
@ $13.39, valued at
$26.8
Bought 40 shares
@ $7.6, valued at
$304 |
|
| 10/02/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/02/2020 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 06/29/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/17/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/03/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/15/2019 |
4
| Bazemore Todd (COO) has filed a Form 4 on Kala Pharmaceuticals, Inc.|
Txns:
| Granted 175,000 options to buy
@ $3.45, valued at
$603.8k
|
|
| 01/04/2019 |
4
| Bazemore Todd (COO) has filed a Form 4 on Kala Pharmaceuticals, Inc.|
Txns:
| Granted 175,000 options to buy
@ $5.19, valued at
$908.3k
|
|
| 02/09/2018 |
4
| Bazemore Todd (COO) has filed a Form 4 on Kala Pharmaceuticals, Inc.|
Txns:
| Granted 25,000 options to buy
@ $12.86, valued at
$321.5k
|
|
| 11/21/2017 |
4
| Bazemore Todd (COO) has filed a Form 4 on Kala Pharmaceuticals, Inc.|
Txns:
| Granted 172,000 options to buy
@ $19.6, valued at
$3.4M
|
|
| 11/21/2017 |
3
| Bazemore Todd (COO) has filed a Form 3 on Kala Pharmaceuticals, Inc. |